Low affinity sodium-glucose cotransporter

Description:

Description
  • Accession: Q9NY91
  • Swissprot: SC5A4_HUMAN
  • Organism: Homo sapiens
  • Gene: SLC5A4
  • Target class: Transporter

Drug Relations:

dapagliflozin
an Sodium-glucose cotransporter 2 (SGLT2) inhibitor, SGLT2 expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen, by inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion Bioactivity details MOA
ertugliflozin
SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Ertugliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Bioactivity details MOA